{"organizations": [], "uuid": "7a7e6d9592b7696dc3b8e3225ae43b26cc80d768", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-viela-bio-spins-out-of-medimmune-r/brief-viela-bio-spins-out-of-medimmune-raises-up-to-250-million-in-series-a-financing-idUSASB0C7XJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Viela Bio Spins Out Of Medimmune Raises Up To $250 Million In Series A Financing", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T12:38:00.000+02:00", "replies_count": 0, "uuid": "7a7e6d9592b7696dc3b8e3225ae43b26cc80d768"}, "author": "", "url": "https://www.reuters.com/article/brief-viela-bio-spins-out-of-medimmune-r/brief-viela-bio-spins-out-of-medimmune-raises-up-to-250-million-in-series-a-financing-idUSASB0C7XJ", "ord_in_thread": 0, "title": "BRIEF-Viela Bio Spins Out Of Medimmune Raises Up To $250 Million In Series A Financing", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "medimmune", "sentiment": "negative"}, {"name": "temasek", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "astrazeneca plc", "sentiment": "none"}, {"name": "astrazeneca", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "  in 19 minutes BRIEF-Viela Bio Spins Out Of Medimmune Raises Up To $250 Million In Series A Financing Reuters Staff 1 Min Read Feb 28 (Reuters) - Astrazeneca Plc: * VIELA BIO SPINS OUT OF MEDIMMUNE; RAISES UP TO $250 MILLION IN SERIES A FINANCING, 6 DIMENSIONS CAPITAL LEADS INVESTMENT * VIELA BIO ​- ‍ SERIES A ROUND CO-LED BY 6 DIMENSIONS CAPITAL, BOYU CAPITAL, HILLHOUSE CAPITAL, WITH PARTICIPATION FROM TEMASEK AND SIRONA CAPITAL * VIELA BIO SAYS ‍ASTRAZENECA WILL REMAIN LARGEST MINORITY SHAREHOLDER OF VIELA BIO * VIELA BIO SAYS ‍MEDIMMUNE TO CONTRIBUTE THREE CLINICAL, THREE PRECLINICAL POTENTIAL NEW MEDICINES TO CO, INCLUDING INEBILIZUMAB  ", "external_links": [], "published": "2018-02-28T12:38:00.000+02:00", "crawled": "2018-02-28T13:02:21.003+02:00", "highlightTitle": ""}